Compare Intel Corp (INTC) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs Merck & Co., Inc. — how do they compare? Intel Corp trades at $108.75 (market cap $566.04B), while Merck & Co., Inc. trades at $141.98 (market cap $351.28B). The key difference: Intel Corp is the larger of the two by market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Intel Corp for 116 Days and Merck & Co., Inc. for 98 Days on average.
| INTC | MRK | |
|---|---|---|
Market Cap | $566.04B | $351.28B |
Volume | 118,475,837 | 7,969,665 |
Sector | Technology | Health |
52-Week High | $140.94 | $156.43 |
52-Week Low | $33.62 | $82.49 |
Typical Hold Time | 116 Days | 98 Days |
Enterprise Value | $586.85B | $398.04B |
Dividend Yield | 2.24% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $113.12, up 0.55% today, with a bullish technical signal and recent earnings beats. The stock has surged over 220% in 2026, driven by AI momentum and foundry growth, though fundamentals show negative net income margins and elevated valuations. Cash flow improved in 2025, but revenue remains below 2022 peaks amid intense competition.
Outlook hinges on foundry turnaround execution; upside exists if Intel captures external customers for advanced nodes, but high debt and margin pressures pose risks. Analyst consensus is cautious with a $111.72 target, slightly below current price, reflecting skepticism on sustainability despite recent gains.
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
